VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant ...

Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed ...

Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million ...

The drug, vepdegestrant, failed to meaningfully delay cancer progression for all patients enrolled in the study but met its ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Arvinas (ARVN) and Pfizer (PFE) announced topline results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus ...

Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+ ...

Pfizer (NYSE:PFE) announced positive outcomes from the Phase 3 VERITAC-2 clinical trial, showing vepdegestrant's promise in ...

and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial ...

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...